Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report.
Transpl Immunol
; 85: 102079, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38964516
ABSTRACT
BACKGROUND:
Liver transplantation (LT) is a unique and effective method for treating end-stage liver diseases and acute liver failure, bringing hope to many patients with liver cancer. LT is currently widely used in the treatment of liver diseases. However, there have been no patients with liver cancer who have undergone ABO-incompatible (ABOi) LT after treatment with the programmed cell death protein 1 (PD-1) inhibitor reported in the literature. CASE PRESENTATION A patient with liver cancer who received sintilimab injection, an anti-PD1 therapy, before LT was admitted in the transplantation centre. This patient underwent ABOi LT. The perioperative treatment strategy of this patient was reported. A desensitisation protocol was conducted urgently for the patient before operation, and the immunosuppression programme of LT was adjusted. After operation, isoagglutinin titer and liver function indicators were strictly monitored. The patient recovered well after operation, and no sign of rejection reaction was observed.CONCLUSION:
We reported a patient with hepatocellular carcinoma (HCC) who received PD-1 inhibitor treatment before operation and successfully underwent ABOi LT. The present case report provides novel insights into the perioperative management of utilizing PD-1 inhibitors prior to ABOi LT in patients diagnosed with hepatocellular carcinoma (HCC).Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Sistema del Grupo Sanguíneo ABO
/
Trasplante de Hígado
/
Carcinoma Hepatocelular
/
Anticuerpos Monoclonales Humanizados
/
Receptor de Muerte Celular Programada 1
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias Hepáticas
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2024
Tipo del documento:
Article